País: Estados Unidos
Idioma: inglés
Fuente: NLM (National Library of Medicine)
AMOXICILLIN (UNII: 804826J2HU) (AMOXICILLIN ANHYDROUS - UNII:9EM05410Q9), CLAVULANATE POTASSIUM (UNII: Q42OMW3AT8) (CLAVULANIC ACID - UNII:23521W1S24)
Rebel Distributors Corp
AMOXICILLIN
AMOXICILLIN ANHYDROUS 400 mg in 5 mL
ORAL
PRESCRIPTION DRUG
Amoxicillin and Clavulanate Potassium is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower Respiratory Tract Infections − caused by β-lactamase−producing strains of H. influenzae and M. catarrhalis . Otitis Media − caused by β-lactamase−producing strains of H. influenzae and M. catarrhalis . Sinusitis − caused by β-lactamase−producing strains of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections − caused by β-lactamase−producing strains of S. aureus , E. coli , and Klebsiella spp. Urinary Tract Infections − caused by β-lactamase−producing strains of E. coli , Klebsiella spp. and Enterobacter spp. While Amoxicillin and Clavulanate Potassium is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with Amoxicillin and Clavulanate Potassium due to its amoxicillin content. Therefore, mixed infections caused by ampicilli
Amoxicillin and Clavulanate Potassium 400 mg/57 mg per 5 mL for Oral Suspension: Each 5 mL of reconstituted orange-flavored suspension contains 400 mg amoxicillin and 57 mg clavulanic acid as the potassium salt. NDC 42254-282-00 100 mL bottle Store tablets and dry powder at or below 25°C (77°F). Dispense in original containers. Store reconstituted suspension under refrigeration. Discard unused suspension after 10 days.
New Drug Application
AMOXICILLIN AND CLAVULANATE POTASSIUM- AMOXICILLIN AND CLAVULANATE POTASSIUM POWDER, FOR SUSPENSION REBEL DISTRIBUTORS CORP ---------- AMOXICILLIN AND CLAVULANATE POTASSIUM POWDER FOR ORAL SUSPENSION AND CHEWABLE TABLETS Rx Only Issued: November 2011 To reduce the development of drug-resistant bacteria and maintain the effectiveness of Amoxicillin and Clavulanate Potassium and other antibacterial drugs, Amoxicillin and Clavulanate Potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Amoxicillin and Clavulanate Potassium is an oral antibacterial combination consisting of the semisynthetic antibiotic amoxicillin and the β-lactamase inhibitor, clavulanate potassium (the potassium salt of clavulanic acid). Amoxicillin is an analog of ampicillin, derived from the basic penicillin nucleus, 6-aminopenicillanic acid. The amoxicillin molecular formula is C H N O S•3H O, and the molecular weight is 419.46. Chemically, amoxicillin is (_2S,5R,6R _)-6-[(_R_)-(-)-2-Amino-2-(_p_- hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate and may be represented structurally as: Clavulanic acid is produced by the fermentation of _Streptomyces clavuligerus_. It is a β-lactam structurally related to the penicillins and possesses the ability to inactivate a wide variety of β-lactamases by blocking the active sites of these enzymes. Clavulanic acid is particularly active against the clinically important plasmid-mediated β-lactamases frequently responsible for transferred drug resistance to penicillins and cephalosporins. The clavulanate potassium molecular formula is C H KNO , and the molecular weight is 237.25. Chemically, clavulanate potassium is potassium (_Z_)-(_2R,5R _)-3-(2- hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]-heptane-2-carboxylate and may be represented structurally as: INACTIVE INGREDIENTS: Powder for Oral Suspension—Colloidal silicon dioxide, flavorings (see HOW SUPPLIED), Leer el documento completo